Company / Accounts Receivable
Immunocore Holdings plc Accounts Receivable History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$63.0M
FY2024
5-year range
$33.6M / $63.0M
FY2022-FY2024
Trend
+21.0%
vs FY2023
Sector context
#65 of 113
Health Care
What the data says
At $63M, Immunocore Holdings plc's accounts receivable ranks #65 of 113 in the Health Care sector. Improved from $34M to $63M over the past 2 years.
Based on SEC 10-K filings.
$63M in FY2024.
Improved from $34M to $63M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#65 of 113 in Health CareTop 58% of 113This company $63.0M Sector average $1.1B
▼
-94.5% below sector average
Key checks
Key Insights
- In FY2024, accounts receivable increased 21.0% year-over-year.
- Ranks #65 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.32 (distress zone, below 1.8 threshold)
- Negative profit margin: -16.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $63.0M | +21.0% |
| FY2023 | $52.1M | +55.1% |
| FY2022 | $33.6M | - |
| FY2021 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026